ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.80
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      63,033.90
      -1.11%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Cellectis SA (CLLS)

      7. Cellectis SA (CLLS) News

      CLLS Cellectis SA

      2.5056
      0.0156 (0.63%)
      Apr 26 2024 - Closed
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      Cellectis SA CLLS NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      0.0156 0.63% 2.5056 16:30:00
      Open Price Low Price High Price Close Price Prev Close
      2.51 2.35 2.51 2.5056 2.49
      more quote information »

      Recent News

      Date Time Source Heading
      4/22/202416:30GLOBECellectis Presents Novel TALEN® Editing Processes Enabling..
      4/10/202416:30GLOBECellectis Publishes a Novel Intronic Gene Editing Approach..
      4/08/202416:30GLOBECellectis Announces Two Poster Presentations on Novel TALEN®..
      1/16/202416:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/16/202416:30GLOBECellectis announces the drawdown of the second tranche of..
      12/22/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/22/202316:30GLOBECellectis Reports Results from Shareholders Meeting Held on..
      12/22/202316:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/05/202316:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/17/202316:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/17/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/17/202316:30GLOBECellectis’ Shareholders Meeting to be Held on December 22,..
      11/15/202307:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/15/202302:30GLOBECellectis Announces the execution of the Subsequent..
      11/09/202316:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/06/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/06/202316:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/06/202316:30GLOBECellectis Reports Financial Results for Third Quarter and..
      11/02/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/02/202316:30GLOBECellectis to Present Preliminary Results of NATHALI_01 and..
      11/01/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/01/202316:30GLOBECellectis to Report Third Quarter 2023 Financial Results on..
      11/01/202315:15APSBiotech Shares Soar After AstraZeneca Stake & Research..
      11/01/202307:52DJNCellectis Shares Soar Premarket on AstraZeneca Deal
      11/01/202307:51DJNCellectis Shares Soar Premarket on AstraZeneca Deal
      11/01/202306:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/01/202304:17DJNAstraZeneca to Invest $245 Million in Deal With Cellectis
      11/01/202303:00GLOBECellectis Announces Strategic Collaboration and Investment..
      10/31/202317:10EDGAR2Form 20-F/A - Annual and transition report of foreign..
      10/31/202317:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/31/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/31/202316:30GLOBECellectis Presents Pre-Clinical Data on Multi-armored..
      10/24/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/12/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/12/202316:30GLOBECellectis and Imagine Institute Publish A Proof-Of-Concept..
      9/27/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/27/202316:30GLOBECellectis to Present Pre-Clinical Data on Multi-armored..
      9/05/202316:32EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
      8/07/202317:05EDGAR2Form S-8 - Securities to be offered to employees in employee..
      8/07/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      8/07/202316:30GLOBECellectis Provides Full Report for Second Quarter 2023..
      8/07/202316:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      8/03/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      8/03/202316:30GLOBECellectis Provides Business Updates and Preliminary..
      7/27/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      7/27/202316:30GLOBECellectis to Report Second Quarter 2023 Financial Results on..
      7/12/202316:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      7/12/202316:30GLOBECellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board..
      6/29/202308:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      6/28/202316:57EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

      Your Recent History

      NASDAQ
      CLLS
      Cellectis
      Delayed Upgrade Clock